Testicular cancer management: Population-wide, rapid case ascertainment to drive early expert engagement and reduced practice variation.

Authors

null

Andrea Harzstark

Kaiser Permanente, Oakland, CA

Andrea Harzstark, Lisa J. Herrinton, Lauren C. Walker, Liyan Liu, Tatjana Kolevska, Mark St. Lezin, Craig R. Nichols, Siamak Daneshmand, Joseph Presti

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

On-Demand Poster Session: Cost, Value, and Policy

Track

Cost, Value, and Policy

Sub Track

Value-Based Models of Care

Citation

J Clin Oncol 38, 2020 (suppl 29; abstr 39)

DOI

10.1200/JCO.2020.38.29_suppl.39

Abstract #

39

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Genitourinary Cancers Symposium

North American patterns of care in clinical stage I testicular cancer from SWOG S1823.

North American patterns of care in clinical stage I testicular cancer from SWOG S1823.

First Author: Antoine Morin Coulombe

Poster

2023 ASCO Annual Meeting

The impact of the 4R Oncology model on OncotypeDx turnaround time.

The impact of the 4R Oncology model on OncotypeDx turnaround time.

First Author: Jenny Wei

Poster

2022 ASCO Genitourinary Cancers Symposium

Evaluating the discriminatory capacity of miR-371A-3P in the context of pure seminomatous testicular cancer metastases.

Evaluating the discriminatory capacity of miR-371A-3P in the context of pure seminomatous testicular cancer metastases.

First Author: Bendu Konneh

Poster

2022 ASCO Genitourinary Cancers Symposium

Accuracy of germ cell tumor histological subtype and stage within the Canadian cancer registry.

Accuracy of germ cell tumor histological subtype and stage within the Canadian cancer registry.

First Author: Patrick Holland